Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
															Search
		×
			Vaccines site
			Vaccines site
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


ChildVaxView


Facebook
        Twitter
        LinkedIn
        Syndicate





Supplementary figures and table for Vaccination Coverage by Age 24 Months Among Children Born in 2015 and 2016 – National Immunization Survey-Child, United States, 2016-2018										Related Pages
										On This Page
			Supplementary Table 1Supplementary Figure 1Supplementary Figure 2
		
SUPPLEMENTARY TABLE 1. Vaccination coverage estimates for bridging cohort,* National Immunization Survey-Child, United States, 2017-2018.
SUPPLEMENTARY TABLE 1. Vaccination coverage estimates for bridging cohort,* National Immunization Survey-Child, United States, 2017-2018.
Children Born January 2015 through May 2016Survey Year 2017
Survey Year 2018
Difference (2018 – 2017)
P-value for Test of Difference=0Vaccine
Estimate
SE
Estimate
SE
Estimate
SE≥3 DTaP by 19 months†
93.2
0.57
93.2
0.45
0.0
0.73
0.963≥4 DTaP by 19 months†
71.4
1.14
70.1
1.05
-1.2
1.55
0.423≥3 Poliovirus by 19 months
91.1
0.75
91.4
0.53
0.3
0.92
0.756≥1 MMR by 19 months§
87.1
0.82
88.1
0.67
1.0
1.06
0.355Hib primary series by 19 months¶
92.9
0.54
92.0
0.56
-0.9
0.78
0.262Hib full series by 19 months¶
75.6
0.99
74.6
0.99
-0.9
1.40
0.505HepB birth dose**
75.3
1.16
74.4
1.03
-0.9
1.55
0.555≥3 HepB by 19 months
90.9
0.62
90.4
0.68
-0.5
0.92
0.595≥1 VAR by 19 months§
87.0
0.77
87.1
0.69
0.0
1.04
0.977≥3 PCV by 19 months
91.7
0.65
91.4
0.59
-0.3
0.88
0.703≥4 PCV by 19 months
78.2
0.97
77.0
0.97
-1.2
1.37
0.383≥1 HepA by 19 months
80.9
0.85
80.4
0.86
-0.5
1.21
0.663≥2 HepA by 19 months
23.9
0.98
25.6
1.00
1.7
1.40
0.234Rotavirus by 19 months††
74.5
1.15
74.1
1.05
-0.4
1.55
0.806Combined 7-vaccine series by 19 months§§
60.4
1.21
59.7
1.15
-0.7
1.67
0.682No vaccinations
1.0
0.12
1.1
0.16
0.1
0.20
0.521**Abbreviations:** DTaP = diphtheria, tetanus toxoids, and acellular pertussis vaccine; HepA = hepatitis A vaccine; HepB = hepatitis B vaccine; Hib = *Haemophilus influenzae* type b conjugate vaccine; MMR = measles, mumps, and rubella vaccine; PCV = pneumococcal conjugate vaccine; SE = standard error; VAR = varicella vaccine.
* The bridging birth cohort used for this analysis includes children born between January 2015 and May 2016.† Includes children who may have been vaccinated with diphtheria and tetanus toxoids vaccine or diphtheria, tetanus toxoids, and pertussis vaccine.§ Includes children who may have been vaccinated with measles, mumps, rubella, and varicella combination vaccine.¶ Hib primary series: receipt of ≥2 or ≥3 doses, depending on product type received; full series: primary series and booster dose, which includes receipt of ≥3 or ≥4 doses, depending on  product type received.
** One dose HepB administered from birth through age 3 days.†† Includes ≥2 doses of Rotarix monovalent rotavirus vaccine (RV1), or ≥3 doses of RotaTeq pentavalent rotavirus vaccine (RV5). The maximum age for the final rotavirus dose is 8 months, 0 days.§§ The combined 7-vaccine series (4:3:1:3*:3:1:4) includes ≥4 doses of DTaP, ≥3 doses of poliovirus vaccine, ≥1 dose of measles-containing vaccine, the full series of Hib (≥3 or ≥4 doses, depending on product type), ≥3 doses of HepB, ≥1 dose of VAR, and ≥4 doses of PCV.

SUPPLEMENTARY FIGURE 1. Estimated Vaccination Coverage by Age 24 Months,* by Birth Year,† National Immunization Survey-Child 2012-2018, United States
SUPPLEMENTARY FIGURE 1. Estimated Vaccination Coverage by Age 24 Months,* by Birth Year,† National Immunization Survey-Child 2012-2018, United States**Abbreviations:** DTaP = diphtheria, tetanus toxoids, and acellular pertussis vaccine; HepA = hepatitis A vaccine; HepB = hepatitis B vaccine; Hib = *Haemophilus influenzae* type b conjugate vaccine; MMR = measles, mumps, and rubella vaccine; PCV = pneumococcal conjugate vaccine; VAR = varicella vaccine.
* Includes vaccinations received by age 24 months (before the day the child turns 24 months), except for the HepB birth dose, rotavirus vaccination, and ≥2 HepA doses by 35 months. For all vaccines except the
HepB birth dose and rotavirus vaccination, the Kaplan-Meier method was used to estimate vaccination coverage to account for children whose vaccination history was ascertained before age 24 months (35 months for ≥2 HepA doses).
† Children born in 2011 are included in survey years 2012, 2013, and 2014; children born in 2012 are included in survey years 2013, 2014, and 2015; children born in 2013 are included in survey years 2014, 2015, and 2016, children born in 2014 are included in survey years 2015, 2016, and 2017; children born in 2015 are included in survey years 2016, 2017, and 2018; children born in 2016 are included in survey years 2017 and 2018 (data from survey year 2019 are not yet available). Linear relationship between year of birth and vaccination status was estimated based on weighted linear regression analysis using the inverse of
The estimated variance of each point estimate to construct the weights. Estimated percentage point change over one birth year (95% confidence interval): ≥4 DTaP -0.2 (-0.6-0.2) ; ≥3 Poliovirus 0.0 (-0.6-0.5); ≥1 MMR 0.0 (-0.3-0.3); Hib full series -0.1 (-0.5-0.3); HepB birth dose 0.4 (-0.8-1.6); ≥3 HepB 0.1 (-0.6-0.7) ; ≥1 Varicella 0.1 (-0.3-0.4) ; ≥4 PCV -0.1(-0.6-0.4); ≥2 HepA (35 mo) 1.1 (0.4-1.8); Rotavirus 0.6 (0.0-1.2); ≥2 Influenza 0.7 (-0.4-1.8); 7-vaccine series 0.1 (-0.3-0.4).
§ Includes children who may have been vaccinated with diphtheria and tetanus toxoids vaccine or diphtheria, tetanus toxoids, and pertussis vaccine.
¶ Includes children who may have been vaccinated with measles, mumps, rubella, and varicella combination vaccine.
** Hib full series: primary series and booster dose, which includes receipt of ≥3 or ≥4 doses, depending on product type received.
†† One dose HepB administered from birth through age 3 days.
§§ Includes ≥2 doses of Rotarix monovalent rotavirus vaccine (RV1), or ≥3 doses of RotaTeq pentavalent rotavirus vaccine (RV5). The maximum age for the final rotavirus dose is 8 months, 0 days.
¶¶ Doses must be at least 24 days apart (four weeks with a four-day grace period).
*** The combined 7-vaccine series (4:3:1:3*:3:1:4) includes ≥4 doses of DTaP, ≥3 doses of poliovirus vaccine, ≥1 dose of measles-containing vaccine, the full series of Hib (≥3 or ≥4 doses, depending on product type), ≥3 doses of HepB, ≥1 dose of VAR, and ≥4 doses of PCV.

SUPPLEMENTARY FIGURE 2. Estimated percentage of children who received no vaccinations by age 24 months,* by birth year†–National Immunization Survey-Child 2012-2018, United States
SUPPLEMENTARY FIGURE 2. Estimated percentage of children who received no vaccinations by age 24 months,* by birth year†--National Immunization Survey-Child 2012-2018, United States**Abbreviations:** CI = confidence interval
* Kaplan-Meier techniques are used to calculate estimates by age 24 months.
† Children born in 2011 are included in survey years 2012, 2013, and 2014; children born in 2012 are included in survey years 2013, 2014, and 2015; children born in 2013 are included in survey years 2014, 2015, and 2016, children born in 2014 are included in survey years 2015, 2016, and 2017; children born in 2015 are included in survey years 2016, 2017, and 2018; children born in 2016 are included in survey years 2017 and 2018 (data from survey year 2019 are not yet available). Estimated linear relationship between year of birth and vaccination status, based on weighted linear regression analysis using the inverse of the estimated variance of each point estimate to construct the weights. Observed percent unvaccinated (95% confidence interval):  2011 0.9 (0.7-1.1); 2012 1.1 (0.8-1.4); 2013 1.1 (0.8-1.4), 2014 1.2 (1.0-1.5); 2015 1.3 (1.1-1.6); 2016 1.2 (0.9-1.6). Estimated percentage point change per year: 0.09 (0.04-0.14).
							
					
						Page last reviewed:  October 9, 2019					Content source: 	National Center for Immunization and Respiratory Diseases ChildVaxView Home
ChildVaxView Interactive!
Publications and Resources
Data Source
Objectives, Targets, and Indicators
For Specific Groupsplus icon
Health Care Professionals
Parents
NIS-Child Survey Participants
Media SchoolVaxView
TeenVaxView
AdultVaxView
FluVaxView
COVIDVaxView
Association of Immunization Managers (AIM)external icon


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue